Case report

_Burkholderia multivorans_: A rare yet emerging cause of bacterial meningitis

Diego P. Peralta\textsuperscript{a,}\textsuperscript{*}, Aymara Y. Chang\textsuperscript{b}, Angie Ariza-Hutchinson\textsuperscript{b}, Catherine A. Ho\textsuperscript{c}

\textsuperscript{a}Division of Infectious Diseases, Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX, 79905, USA
\textsuperscript{b}Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX, 79905, USA
\textsuperscript{c}Department of Pharmacy, University Medical Center of El Paso, El Paso, TX, 79905, USA

**A R T I C L E  I N F O**

Keywords:
Burkholderia multivorans
Burkholderia cepacia complex
Meningitis
Trimethoprim/sulfamethoxazole

**A B S T R A C T**

_Burkholderia multivorans_ is a member of the _Burkholderia cepacia_ complex. Although it is usually associated with infections in patients with cystic fibrosis, chronic granulomatous disease, and immunosuppression, central nervous infections are not commonly reported. Moreover, management of these infections is difficult due to multiple mechanisms of bacterial resistance to antimicrobial agents. We report a 55-year-old-man who developed _Burkholderia multivorans_ meningitis after two episodes of central line-associated bloodstream infections. The patient was successfully treated with intravenous trimethoprim/sulfamethoxazole. _Burkholderia multivorans_ is an emerging cause of meningitis with limited antibacterial treatment options. However, trimethoprim/sulfamethoxazole remains an effective agent with excellent penetration into the central nervous system. To our knowledge, this is the first case reported of _Burkholderia cepacia_ complex meningitis identified to the species level as _Burkholderia multivorans._

**Introduction**

_Burkholderia multivorans_ (formally known as _Pseudomonas cepacia_ and _Burkholderia cepacia_ genomovar II) is an aerobic, glucose non-fermenting, gram-negative bacillus and member of the _Burkholderia cepacia_ complex (BCC)\textsuperscript{1}. The BCC is a group of opportunistic pathogens that can be found in soil and water\textsuperscript{2,3}. There are 17 different and highly virulent species in the complex that are primarily associated with causing infections in patients with cystic fibrosis (CF), chronic granulomatous disease (CGD), and immunosuppression\textsuperscript{2,4–7}. Nosocomial infections have also been reported through contaminated anesthetic solutions, water sources, medical devices, disinfectants, and non-sterile medical products\textsuperscript{3,5,8–10}. Infections of the central nervous system have been previously described\textsuperscript{11–13}, but there are no reports, to our knowledge, specifically of _Burkholderia multivorans_ meningitis.

**Case**

A 55-year-old-man presented with two days of fever, chills, nausea, vomiting, and abdominal pain followed by deterioration of his mental status. His medical history included hypertension, seizure disorder, and multiple myeloma (MM) which was treated with chemotherapy and homologous stem cell transplantation (HSCT) three years before admission. Ongoing maintenance chemotherapy was continued with carfilzomib, pomalidomide, and dexamethasone after undergoing HSCT. He also underwent a craniectomy during his childhood to correct an arteriovenous malformation (AVM).

Six months before this admission, he had developed pneumonia and two episodes of _Burkholderia cepacia_ central line-associated bloodstream infections (CLABSI) that were treated with intravenous trimethoprim/sulfamethoxazole (TMP/SMX) and had the most recent antibacterial treatment two weeks before presentation. Moreover, he developed a catheter-associated deep venous thrombosis (DVT) of the left upper extremity that was managed with catheter removal and anticoagulation. Of note, his chemotherapy was placed on hold after he developed pneumonia.

Upon examination, he was febrile (38.5 °C), bradycardic (44 bpm), and had epigastric tenderness with palpation. He was confused with a Glasgow coma scale of 13/15 (E3, V4, M6). There was no neurological deficits or meningeal signs. The rest of his examination was not remarkable. An initial head CT showed diffuse ventricular enlargement without transepidual fluid migration, concerning for elevated intracranial pressure. This suspicion, however, was dismissed after neurosurgery evaluation. A lumbar puncture was performed after anti-Xa levels were reported as undetectable. Cerebrospinal fluid (CSF) was colorless and slightly hazy, RBC 30/mm\(^3\), WBC 910/mm\(^3\) with 94% neutrophils, glucose 10 mg/dL, and proteins 162 mg/dL (Table 1). He...
received empiric intravenous vancomycin, ampicillin, cefepime and TMP/SMX since CSF features were compatible with bacterial meningitis. Within the next 48 h, a gram-negative rod, later identified as *Burkholderia multivorans*, grew in both CSF and blood cultures (Fig. 1).

The VITEK® MS, VITEK® 2, and Etest® (bioMérieux, Marcy-l’Étoile, France) were used for microbial identification and antibacterial susceptibility, respectively (Table 2). The bacterial identification and susceptibility were confirmed at the state reference laboratory.

The patient’s therapy was streamlined to TMP/SMX alone as it was the only agent exhibiting antibacterial activity with a minimal inhibitory concentration of 0.75 μg/ml by Etest® and 1/16 μg/ml by VITEK® 2. A transesophageal echocardiogram performed did not show evidence of endocarditis. Repeated CSF and blood cultures proved clearance of *Burkholderia multivorans*, demonstrating the effectiveness of TMP/SMX treatment. He completed a total of 21 days of intravenous TMP/SMX therapy after obtaining negative CSF cultures.

**Discussion**

This case illustrates *Burkholderia multivorans* as a rare but emerging cause of bacterial meningitis and the complexity of its management due to the bacterium’s multiple mechanisms of antimicrobial resistance. With this in mind, our case provides a unique account because *Burkholderia multivorans* has never been reported as a specific cause of bacterial meningitis. Although reports of BCC meningitis exist [11–13], isolates were never identified to the species level as seen with our patient. The identification of the BCC species is usually difficult due to the phenotypic and genotypic similarities among them and other *Burkholderia* species outside of the BCC [3]. In our patient, *Burkholderia multivorans* was initially identified using the VITEK® MS system in our facility and confirmed at the state reference laboratory.

Multiple risk factors including MM-associated immunosuppression, maintenance chemotherapy, extensive healthcare exposure, and prolonged use of a central venous catheter ultimately led to our patient’s likely acquisition of this *Burkholderia multivorans* infection. Patients with MM have abnormalities in both cellular and humoral immunity that increase the risk of infection. Those defects include hypogammaglobulinemia, low number and anomalous function of dendritic and T cells, abnormal Th1/Th2 CD4+ ratio, disruption of T cell diversity, and dysfunction of natural killer cells [14,15]. MM treatment also increases the risk for infections, cytopenias, and thrombotic events [16–19]. These complications are underscored in this case by the

### Table 1

| Appearance Spun | Reference Range | Day 1 | Day 4 | Day 7 | Day 10 | Day 16 |
|----------------|----------------|------|------|------|-------|-------|
| RBC            | < 5 cells/μL   | 30   | 530  | 14400| 1600  | 10    |
| WBC            | < 5 cells/μL   | 910  | 260  | 384  | 5     | 95    |
| Neutrophils    | %              | 94   | 88   | 69   | 26    | 14    |
| Lymphocytes    | %              | 6    | 7    | 15   | 66    | 78    |
| Monocytes      | %              | None Seen | 5 | 16 | 8 | 8 |
| Glucose        | 40–75 mg/dL    | 10   | 24   | 38   | 36    | 49    |
| Proteins       | 15–45 mg/dL    | 162  | 102  | 196  | 121   | 175   |

**Table 2**

*Burkholderia multivorans* susceptibility profile.

| Antibiotic       | CSF          | Blood        |
|------------------|--------------|--------------|
|                  | Etest®       | VITEK® 2     | Etest®       | VITEK® 2     |
|                  | MIC (μg/mL)  | Interpretation | MIC (μg/mL)  | Interpretation |
| Amikacin         | 256 R        | > 64 R       | 256 R        | > 64 R       |
| Cefepime         | 256 R        | > 64 R       | 256 R        | > 64 R       |
| Ceftazidime      | 256 R        | > 64 R       | 256 R        | > 64 R       |
| Ciprofloxacin    | 32 R         | > 4 R        | 32 R         | > 4 R        |
| Colistin         | 256 R        | > 16 R       | 256 R        | > 16 R       |
| Gentamicin       | 256 R        | > 16 R       | 256 R        | > 16 R       |
| Levofloxacin     | 32 R         | > 8 R        | 32 R         | > 8 R        |
| Mersopenem       | 32 R         | > 16 R       | 32 R         | > 16 R       |
| Minocycline      | 8 I          | I            | 8 I          | I            |
| Piperacillin     | 256 R        | > 128 R      | 256 R        | > 128 R      |
| Piperacillin/Tazobactam | 256 R     | > 128/4 R    | 256 R        | > 128/4 R    |
| Trimethoprim/Sulfamethoxazole | 0.75 S | 1/16 S | 0.75 S | 1/16 S |

*Fig. 1. Burkholderia multivorans* colonies in Blood (A), Chocolate (B), MacConkey (C), and Burkholderia Cepacia Selective (D) agars.
patient developing pneumonia, DVT, CLABSI, and meningitis after receiving maintenance chemotherapy with carbfilomib, pomalidomide, and dexamethasone. The patient spent several weeks in different healthcare facilities, increasing the exposure risk to nosocomial pathogens. The prolonged use of a central venous catheter was likely the port of entry for *Burkholderia multivorans* and consequently led to the patient’s CLABSI and meningitis.

**BCC management is challenging due to its ability to evade the action of multiple antimicrobials through intrinsic and acquired resistance mechanisms [2,5]. Those mechanisms include the production of β-lactamas, carbapenemases, and antibacterial drug efflux pumps as well as the ability to decrease the number of membrane porins, modify bacterial lipopolysaccharide structure, and mutate antimicrobial binding targets [2]. Although these resistance mechanisms have limited our antimicrobial armamentarium against BCC infections, certain isolates can show susceptibility to beta-lactams including ceftazidime, meropenem, and piperacillin. These medications are considered alternatives to TMP/SMX, the primary regimen for therapy and prophylaxis of BCC infections. Moreover, beta-lactams can be used as a treatment option when patients have an intolerance, allergy, or resistance to TMP/SMX [5].**

In this case, only TMP/SMX showed activity against the isolate which confirms the resilience of *Burkholderia multivorans* to therapy and supports TMP/SMX as an effective option to treat *Burkholderia multivorans* infections including meningitis [11,20]. Due to its lipophilic properties, TMP/SMX efficiently penetrates into the CSF in both the absence and the presence of meningeal inflammation [21].

**Conclusion**

*Burkholderia multivorans* is a rare yet emerging cause of meningitis as demonstrated in our case. Although *Burkholderia multivorans* is commonly isolated in patients with CF and CGD, nosocomial infections are increasing in number. Its complex antimicrobial susceptibility profile in conjunction with its ability to evade multiple antimicrobials makes its management quite complicated. TMP/SMX remains useful in the management of meningitis since it provides excellent penetration into the CSF and retains activity against *Burkholderia multivorans*.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Disclosures**

No financial disclosures or conflict of interests.

**References**

[1] Vandamme P, Dawyndt P. Classification and identification of the Burkholderia cepacia complex: past, present and future. Syst Appl Microbiol 2011;34:87–95. http://dx.doi.org/10.1016/j.syapm.2010.10.002.

[2] Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Update 2016;28:82–90. http://dx.doi.org/10.1016/j.drup.2016.07.003.

[3] Coenye T, Vandamme P, Govan JRW, Lipuma JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001;39:3427–36. http://dx.doi.org/10.1128/JCM.39.10.3427-3436.2001.

[4] Whitehouse JL, Exley AR, Fowleraker J, Bilton D. Chronic Burkholderia multivorans bronchial infection in a non-cystic fibrosis individual with mannosse binding lectin deficiency. Thorax 2005;60:168–70. http://dx.doi.org/10.1136/thx.2003.016493.

[5] Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AF, Falagas ME. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 2009;33:394–404. http://dx.doi.org/10.1016/j.ijantimicag.2008.09.010.

[6] Schmerk CL, Valvano MA. Burkholderia multivorans survival and trafficking within macrophages. J Med Microbiol 2013;62:173–84. http://dx.doi.org/10.1099/jmm.0.051872.0.

[7] ININ Silva, Santos PM, MMR Santos, Zlonski JE, Speet DP, Busirkw SW, et al. Long-term evolution of Burkholderia multivorans during a chronic cystic fibrosis infection reveals shifting forces of selection. mSystems 2016;1:e00029-16. http://dx.doi.org/10.1128/mSystems.00029-16.

[8] Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004;25:231–9. http://dx.doi.org/10.1086/502384.

[9] De Smet B, Veng C, Kruy L, Kham C, van Grienden J, Peeters C, et al. Outbreak of Burkholderia cepacia bloodstream infections traced to the use of Ringer lactate solution as multiple-dose vial for catheter flushing. Phenom Penh, Cambodia. Clin Microbiol Infect 2013;19:832–7. http://dx.doi.org/10.1111/1469-0691.12047.

[10] Metcalfe P, Newman K, Siegel JD, Pascoe N, Terasihta D, Mascola L, et al. Nosocomial Burkholderia cepacia infections associated with exposure to sublingual probes – Texas, 2004. MMWR Morb Mortal Wkly Rep 2004;53:796.

[11] Darby CP. Treating Pseudomonas cepacia meningitis with trimethoprim-sulfamethoxazole. Am J Dis Child 1976;120:525–30. http://dx.doi.org/10.1001/archpedi.1976.02120130071014.

[12] Kremery V, Havlik J, Vicianová L. Nosocomial meningitis caused by multiply resistant Pseudomonas cepacia. Pediatr Infect Dis J 1987;6:769.

[13] Crispim JN, Damaso C, Marques JG, Miguens J, Valeate P. Burkholderia cepacia meningitis: a case report. J Pediatr Infect Dis 2010;5:396–397. http://dx.doi.org/10.1016/j.jpid.2010.02.001.

[14] Nucci M, Anaisie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211–25. http://dx.doi.org/10.1086/598640.

[15] Pasa S, Alintas A, Cil T, Ustun C, Bayan K, Danis R, et al. Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis? Int J Infect Dis 2009;13:19–22. http://dx.doi.org/10.1016/j.ijid.2008.04.063.

[16] Moreau P, Richardson PG, Cavo M, Orloowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947–59. http://dx.doi.org/10.1182/blood-2012-04-403733.

[17] Lacy MQ, McCurdy AR, Pomalidomide. Blood 2012;122:2305–9. http://dx.doi.org/10.1182/blood-2013-05-504782.

[18] Perel G, Bliss J, Thomas CM. Carfilzomib (Kyprolis): a novel proteasome inhibitor for relapsed and/or refractory multiple myeloma. P T 2016;41:303–7. http://dx.doi.org/10.1182/blood-2013-05-484782.

[19] Foustier K, De Becker A, Schots R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther 2012;5:237–44. http://dx.doi.org/10.2147/OTT.S28911.

[20] Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984;100:981–90.

[21] Nau R, Sørgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010;23:858–83. http://dx.doi.org/10.1128/CMR.0007-10.